FindTrial
Sign In

Paclitaxcel

DRUG2 trials

Sponsors

Shanghai Jiao Tong University School of Medicine, Medical University of South Carolina

Conditions

Elevated Tumor-Infiltrating LymphocytesInduction ChemotherapyInductive TherapyOral CancerProgrammed Cell Death 1 InhibitorTriple Negative Breast Cancer (TNBC)

Phase 1

Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients
CompletedNCT04473716
Shanghai Jiao Tong University School of MedicineInduction Chemotherapy, Inductive Therapy, Oral Cancer +1
Start: 2020-07-30End: 2023-09-30Updated: 2023-11-22

Phase 2

A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)
RecruitingNCT07743190
Medical University of South CarolinaElevated Tumor-Infiltrating Lymphocytes, Triple Negative Breast Cancer (TNBC)
Start: 2026-10-01End: 2030-03-01Target: 55Updated: 2026-08-24

Related Papers

De-escalate surgery of primary lesions after neoadjuvant immune-combination therapy in locally advanced oral squamous cell carcinoma: The 5-year survival results of two single-arm trials.
Journal of Clinical Oncology2026-05-28
Major pathological response to neoadjuvant immune-related therapy and influence on long-term survival in patients with locally advanced oral squamous cell carcinoma.
Journal of Clinical Oncology2025-05-28
Neoadjuvant trial with toripalimab, albumin paclitaxel, and cisplatin on pathological response in locally advanced resectable oral squamous cell carcinoma (Illuminate Trial).
Journal of Clinical Oncology2022-06-014 citations